AI assistant
BeOne Medicines Ltd. — Director's Dealing 2025
Sep 12, 2025
30073_dirs_2025-09-12_7486ffbe-cb5f-422c-8d52-d1102defd251.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeOne Medicines Ltd. (ONC)
CIK: 0001651308
Period of Report: 2025-09-10
Reporting Person: Lee Chan Henry (SVP, General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-10 | American Depositary Shares | S | 1112 | $325 | Disposed | 0 | Direct |
| 2025-09-10 | American Depositary Shares | M | 6802 | $194.47 | Acquired | 6802 | Direct |
| 2025-09-10 | American Depositary Shares | M | 1796 | $213.32 | Acquired | 8598 | Direct |
| 2025-09-10 | American Depositary Shares | M | 296 | $159.03 | Acquired | 8894 | Direct |
| 2025-09-10 | American Depositary Shares | S | 4776 | $325.1934 | Disposed | 4118 | Direct |
| 2025-09-10 | American Depositary Shares | S | 3318 | $325.7264 | Disposed | 800 | Direct |
| 2025-09-10 | American Depositary Shares | S | 300 | $326.80 | Disposed | 500 | Direct |
| 2025-09-10 | American Depositary Shares | S | 500 | $327.93 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-10 | Share Option (Right to Buy) | $14.96 | M | 88426 | Disposed | 2032-08-04 | Ordinary Shares (88426) | Direct |
| 2025-09-10 | Share Option (Right to Buy) | $16.41 | M | 23348 | Disposed | 2033-06-14 | Ordinary Shares (23348) | Direct |
| 2025-09-10 | Share Option (Right to Buy) | $12.23 | M | 3848 | Disposed | 2034-06-04 | Ordinary Shares (3848) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 237562 | Direct |
Footnotes
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.49 to $325.48, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.50 to $326.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F6: These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F7: These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F8: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.